Latest news
Incyte (INCY) Could Be 5% Overvalued Following Opzelura Approval And Higher Guidance - simplywall.stsimplywall.st · Wed, 05 Aug 2026 08:51:44 GMTThe Bull Case For Incyte (INCY) Could Change Following New EU Opzelura Atopic Dermatitis Approval - webull.comwebull.com · Mon, 03 Aug 2026 13:06:53 GMTWeekly Recap: Incyte Q2 revenue surge and Opzelura second EU indication - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTIncyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In? - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 21:09:41 GMTIncyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 07:00:00 GMTIncyte (INCY) Wins European Approval For Opzelura In Adult Atopic Dermatitis - simplywall.stsimplywall.st · Thu, 30 Jul 2026 11:16:40 GMTNo-Moat Incyte Faces Jakafi Patent Cliff as Focus Remains on Opzelura and Expanding Portfolio - MorningstarMorningstar · Wed, 29 Jul 2026 23:50:19 GMTIncyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod - TradingViewTradingView · Wed, 29 Jul 2026 17:22:11 GMT